TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30109845

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882 mg intramuscular every 4 weeks
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg intramuscular every 4 weeks
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Overall treatment with aripiprazole lauroxil
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Initial injections of aripiprazole lauroxil
Number of subjects: 478
Study: 30110589

Group type: EXPERIMENTAL
Intervention: Ibalizumab (2000 mg loading dose, then 800 mg every 14 days)
Number of subjects: 40
Study: 30111186

Group type: EXPERIMENTAL
Intervention: Quetiapine exposure during first trimester
Number of subjects: 357

Group type: COMPARATOR
Intervention: No second-generation antipsychotic exposure
Number of subjects: 357
Study: 30111326

Group type: EXPERIMENTAL
Intervention: Asthma Control Test (ACT)
Number of subjects: 0
Study: 30111365

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (5000-7000 counts per minute)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Sedentary time and light physical activity
Number of subjects: 841
Study: 30111528

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization followed by sorafenib
Number of subjects: 520

Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 520
Study: 30111609

Group type: EXPERIMENTAL
Intervention: obinutuzumab, ibrutinib, and venetoclax (fixed-duration regimen, 14 cycles of 28 days each)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: obinutuzumab, ibrutinib, and venetoclax (fixed-duration regimen)
Number of subjects: 12
Study: 30112005

Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30g/day for 12 weeks
Number of subjects: 40
Study: 30113201

Group type: EXPERIMENTAL
Intervention: Conscientiousness
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Planning strategies
Number of subjects: 136

Group type: COMPARATOR
Intervention: Support intensity
Number of subjects: 136
Study: 30113351

Group type: EXPERIMENTAL
Intervention: Epileptiform discharges during anaesthesia induction
Number of subjects: 62

Group type: COMPARATOR
Intervention: No epileptiform discharges during anaesthesia induction
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Interictal spike events (rhythmic polyspikes; periodic epileptiform discharges; delta with spikes)
Number of subjects: 62
Study: 30113648

Group type: EXPERIMENTAL
Intervention: Anandamide (AEA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 2-arachidonoylglycerol (2-AG)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (OEA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Specific sphingomyelins (SM18:1/23:0, SM18:1/23:1, SM18:1/26:1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sphingomyelins
Number of subjects: 53
Study: 30113663

Group type: EXPERIMENTAL
Intervention: Skeletal muscle biopsies from women with PCOS
Number of subjects: 31

Group type: COMPARATOR
Intervention: Skeletal muscle biopsies from controls
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Functional follow-up studies on KLF10
Number of subjects: 31
Study: 30113681

Group type: EXPERIMENTAL
Intervention: EHR prescribing data linked to claims-based dispensing data
Number of subjects: 0
Study: 30113685

Group type: EXPERIMENTAL
Intervention: Multimodal Perioperative Pain Protocol (MP3)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (pre-intervention)
Number of subjects: 252
Study: 30113844

Group type: EXPERIMENTAL
Intervention: Dual JAK1/TYK2 inhibitor (PF-06700841)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monoclonal antibodies (mAbs) or JAK1 inhibitors
Number of subjects: 0
Study: 30114960

Group type: EXPERIMENTAL
Intervention: Hyperosmolar CPB prime
Number of subjects: 30
Study: 30115015

Group type: EXPERIMENTAL
Intervention: Lowest education level (lower than high school)
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Completed high school education
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Monthly income level < $1500
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Monthly income level $1500-4500
Number of subjects: 1361

Group type: COMPARATOR
Intervention: Highest education level (reference)
Number of subjects: 1361

Group type: COMPARATOR
Intervention: Monthly income level > $4500 (reference)
Number of subjects: 1361
Study: 30115127

Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 2377
Study: 30115226

Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients with emotional triggers (30% of TTS patients)
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients with physical triggers (39% of TTS patients)
Number of subjects: 1613

Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients with no identifiable trigger (31% of TTS patients)
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Acute coronary syndrome (ACS) patients
Number of subjects: 1613
Study: 30115251

Group type: EXPERIMENTAL
Intervention: Carotid corrected flow time (FTc)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak)
Number of subjects: 53
Study: 30115541

Group type: EXPERIMENTAL
Intervention: Cladribine plus low-dose cytarabine alternating with decitabine for up to 18 cycles (induction therapy: cladribine 5 mg/m²).
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Cladribine plus low-dose cytarabine alternating with decitabine.
Number of subjects: 118
Study: 30115596

Group type: EXPERIMENTAL
Intervention: Bendamustine (70 mg/m²) followed by obinutuzumab and venetoclax
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bendamustine followed by obinutuzumab and venetoclax
Number of subjects: 66
Study: 30115688

Group type: EXPERIMENTAL
Intervention: Quantitative myocardial perfusion severity analysis
Number of subjects: 0
Study: 30115734

Group type: EXPERIMENTAL
Intervention: Itacitinib 300 mg plus chemotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Itacitinib
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 55
Study: 30116539

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study: 30116592

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AAP)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Enzalutamide (ENZ)
Number of subjects: 211
Study: 30117142

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30117149

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m² weekly for 4 cycles
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bendamustine (specific dosage not mentioned)
Number of subjects: 63
Study: 30117309

Group type: EXPERIMENTAL
Intervention: Addiction-based weight loss smartphone app with coaching
Number of subjects: 18

Group type: COMPARATOR
Intervention: EMPOWER clinic program (control)
Number of subjects: 18
Study: 30117761

Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT) - 470 kCal
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intravenous L-arginine (arginine maximal stimulation test - AST, 5 g)
Number of subjects: 62
Study: 30118386

Group type: EXPERIMENTAL
Intervention: MMR-RIT
Number of subjects: 1736

Group type: COMPARATOR
Intervention: MMR II
Number of subjects: 1736
Study: 30118397

Group type: EXPERIMENTAL
Intervention: Proton radiation therapy (RT)
Number of subjects: 222
Study: 30118633

Group type: EXPERIMENTAL
Intervention: Challenge dose of monovalent HBV vaccine
Number of subjects: 302
Study: 30118852

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 315
Study: 30118942

Group type: EXPERIMENTAL
Intervention: BAT + GDMT
Number of subjects: 264

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 264
Study: 30119089

Group type: EXPERIMENTAL
Intervention: Diaphragm pacing system with spinal cord stimulation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Diaphragm pacing system
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 3
Study: 30119715

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 239

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 239
Study: 30119925

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy (received by 402 patients, 48.4%)
Number of subjects: 831
Study: 30120161

Group type: EXPERIMENTAL
Intervention: Regorafenib administered daily for 3 weeks of each 4-week cycle until disease progression or other reason.
Number of subjects: 0
Study: 30120268

Group type: EXPERIMENTAL
Intervention: Indibulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indibulin + Vinblastine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vinblastine and Colchicine
Number of subjects: 0
Study: 30120281

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study: 30120518

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (Dysport) injection cycles
Number of subjects: 150
Study: 30120839

Group type: EXPERIMENTAL
Intervention: Facial electromyography (EMG) during fMRI BOLD sequence
Number of subjects: 16
Study: 30120956

Group type: EXPERIMENTAL
Intervention: Wet heparin suction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dry heparin suction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dry needle biopsy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dry techniques
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dry heparin
Number of subjects: 40
Study: 30121090

Group type: EXPERIMENTAL
Intervention: VA-ECMO support
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lactate levels
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Microcirculatory parameters
Number of subjects: 48
Study: 30121138

Group type: EXPERIMENTAL
Intervention: Cannabinoid CB
Number of subjects: 0
Study: 30121271

Group type: EXPERIMENTAL
Intervention: Breast arterial calcification (BAC) presence
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Low bone mass (LBM) presence
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Addition of BAC presence to 10-year ASCVD risk
Number of subjects: 2100
Study: 30121419

Group type: EXPERIMENTAL
Intervention: Rivaroxaban treatment
Number of subjects: 3797
Study: 30121602

Group type: EXPERIMENTAL
Intervention: Dabrafenib monotherapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dabrafenib in combination with trametinib
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dabrafenib monotherapy or combination therapy
Number of subjects: 84
Study: 30121613

Group type: EXPERIMENTAL
Intervention: Small volume plasma exchange (SVPE)
Number of subjects: 20
Study: 30121827

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg with loading dose
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg without loading dose
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 30121892

Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 53
Study: 30121938

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (RT) at a maximum tolerated dose (MTD) of 20 Gy delivered in 2 days, twice daily.
Number of subjects: 45
Study: 30122202

Group type: EXPERIMENTAL
Intervention: MPN-SAF TSS (Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score); range 0-100
Number of subjects: 2309

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer-Core Quality of Life Questionnaire, version 3.0); range 0-100
Number of subjects: 2309

Group type: EXPERIMENTAL
Intervention: WPAI-SHP (Work Productivity and Activity Impairment Questionnaire-Specific Health Problem); range 0%-100
Number of subjects: 2309
Study: 30122926

Group type: EXPERIMENTAL
Intervention: Asenapine 2.5 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asenapine 5.0 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asenapine 10.0 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30123324

Group type: EXPERIMENTAL
Intervention: Smartphone-based physical activity data collection
Number of subjects: 0
Study: 30123511

Group type: EXPERIMENTAL
Intervention: Echocardiogram-guided resuscitation (ECHO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 30
Study: 30123522

Group type: EXPERIMENTAL
Intervention: Whiteboard animation video for parents about AGE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control video
Number of subjects: 0
Study: 30123525

Group type: EXPERIMENTAL
Intervention: 8 weeks of participation in a rehabilitation program led by a Case Manager
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual community aged care
Number of subjects: 130
Study: 30123524

Group type: EXPERIMENTAL
Intervention: Positive Mental Imagery Training (PMIT) + Treatment as Usual (TAU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CCT) + Treatment as Usual (TAU)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 90
Study: 30123523

Group type: EXPERIMENTAL
Intervention: Esmolol infusion (targeted to heart rate 80-90/min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 7
Study: 30123673

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily during the first 3 cycles of VCD induction therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo tablet twice daily during the first 3 cycles of VCD induction therapy
Number of subjects: 58
Study: 30123846

Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Herbal formulation (HB)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Artificial tears (AT)
Number of subjects: 150
Study: 30123935

Group type: EXPERIMENTAL
Intervention: Amyloid PET imaging
Number of subjects: 97
Study: 30124008

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) injection of bone marrow derived mesenchymal stromal cells (BM-MSCs), n=6
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) injection of bone marrow derived mesenchymal stromal cells (BM-MSCs), n=8
Number of subjects: 14
Study: 30124502

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided BPB
Number of subjects: 15
Study: 30124757

Group type: EXPERIMENTAL
Intervention: Nutrition Literacy (NL)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 320
Study: 30124798

Group type: EXPERIMENTAL
Intervention: Cardioband procedure
Number of subjects: 60
Study: 30124844

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 31
Study: 30124893

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFAs)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Trans fatty acids (TFAs)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Omega-6 linoleic acid
Number of subjects: 1228
Study: 30124968

Group type: EXPERIMENTAL
Intervention: Magnetic resonance cholangiopancreatography (MRCP) screening
Number of subjects: 54
Study: 30125215

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) levels before therapy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Early molecular response (EMR) after one cycle of therapy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Major molecular response (MMR) after two cycles of therapy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Early molecular response (EMR) in salvage therapy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: ctDNA levels and molecular responses
Number of subjects: 217
Study: 30126352

Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling (ASL) perfusion and Diffusion Weighted Imaging (DWI)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Diffusion Weighted Imaging (DWI) without ASL
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI) with ASL
Number of subjects: 116

Group type: COMPARATOR
Intervention: Susceptibility Weighted Imaging (SWI)
Number of subjects: 116
Study: 30126361

Group type: EXPERIMENTAL
Intervention: Screening for MRB colonization using swabs from the nose, throat, and rectum.
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Development of a clinical tool for identifying risk groups for MRB colonization.
Number of subjects: 10000
Study: 30126395

Group type: EXPERIMENTAL
Intervention: Previous knee/hip injury
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: Family history of osteoarthritis
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: Knee/hip injuries and surgeries
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: Persistent knee/hip pain
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: Joint injury and overweight during early adulthood
Number of subjects: 2661
Study: 30126401

Group type: EXPERIMENTAL
Intervention: Objective measurements including lung function and quantitative assessment of airway inflammation and exhaled breath, peripheral blood, skin, nasal, pharyngeal, and nasopharyngeal swabs, nasal secretions, primary nasal epithelial cells, and induced sputum.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized questionnaires and structured interviews, telephone interviews.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular objective measurements and biomaterial collection.
Number of subjects: 0
Study: 30126440

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) in 5 fractions
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) in 3 fractions
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) in 1 fraction
Number of subjects: 90
Study: 30126674

Group type: EXPERIMENTAL
Intervention: Pfs25 VLP-FhCMB vaccine combined with Alhydrogel® adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pfs25 VLP-FhCMB vaccine
Number of subjects: 0
Study: 30126709

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-1 (IGF-1)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 197
Study: 30126765

Group type: EXPERIMENTAL
Intervention: Enzalutamide 1L treatment (chemo-naive)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Enzalutamide 2L treatment (post-docetaxel or -abiraterone)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Enzalutamide 3L or 4L treatment
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Enzalutamide (overall)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Enzalutamide (fatigue incidence)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Enzalutamide 3L or 4L treatment (fatigue)
Number of subjects: 117
Study: 30126861

Group type: EXPERIMENTAL
Intervention: Paclitaxel (70 mg/m2)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Irinotecan
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 112
Study: 30126891

Group type: EXPERIMENTAL
Intervention: Multifaceted medication reconciliation quality improvement intervention
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1648
Study: 30126931

Group type: EXPERIMENTAL
Intervention: Relative drop in platelets >25% at landmark
Number of subjects: 807

Group type: COMPARATOR
Intervention: Relative drop in platelets ≤25% at landmark
Number of subjects: 807
Study: 30126953

Group type: EXPERIMENTAL
Intervention: ETX2514SUL (combination of ETX2514 and sulbactam)
Number of subjects: 0
Study: 30127037

Group type: EXPERIMENTAL
Intervention: Clinical chemistry score (CCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 0
Study: 30127621

Group type: EXPERIMENTAL
Intervention: Combination therapy of oral osimertinib, oral temozolomide, intrathecal cytarabine, and whole-brain radiation therapy
Number of subjects: 1
Study: 30127664

Group type: EXPERIMENTAL
Intervention: Diary written by a close relative of a critically ill patient, with guidance from ICU nurses.
Number of subjects: 200
Study: 30127805

Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 73
Study: 30128164

Group type: EXPERIMENTAL
Intervention: Individualised telemedicine cognitive behavioural therapy (CBT)-based intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Self-guided web-based relaxation programme
Number of subjects: 40
Study: 30128316

Group type: EXPERIMENTAL
Intervention: Drisapersen 6 mg/kg/week for 24 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Drisapersen 3 mg/kg/week for 24 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30128496

Group type: EXPERIMENTAL
Intervention: In vivo confocal microscopy (IVCM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laser scanning confocal microscopy (LSCM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Wide-field imaging
Number of subjects: 30
Study: 30128502

Group type: EXPERIMENTAL
Intervention: PVX-410 vaccine (0.4 mg total, 0.1 mg/peptide, n=3) or (0.8 mg total, 0.2 mg/peptide, n=9) biweekly via subcutaneous injection, plus 0.5 mL (1 mg) poly-ICLC (2 mg/mL) via intramuscular injection with each dose.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of PVX-410 vaccine with lenalidomide (25 mg orally daily for three 21-day cycles, n=10).
Number of subjects: 22

Group type: COMPARATOR
Intervention: PVX-410 vaccine alone (monotherapy).
Number of subjects: 22
Study: 30128591

Group type: EXPERIMENTAL
Intervention: Infectious purpura fulminans
Number of subjects: 306
Study: 30128605

Group type: EXPERIMENTAL
Intervention: Intravitreal decorin 200 μg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravitreal decorin 400 μg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravitreal decorin (both dosages)
Number of subjects: 12